+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years - 75Years
All Genders
ID07617727

Phase I Clinical Trial to Assess Safety, Pharmacokinetics, and Antitumor Activity of JSKN021 in Adults with Advanced Malignant Solid Tumors

Led by Jiangsu Alphamab Biopharmaceuticals Co., Ltd · Updated on 2026-08-26

199

Participants Needed

10

Research Sites

30 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are conducting a Phase I, open-label clinical trial to assess the safety, tolerability, pharmacokinetics, and early antitumor effects of the drug JSKN021 in adults with advanced malignant solid tumors. This first-in-human study aims to understand how JSKN021 behaves in the body and its potential impact on tumors in patients who have not responded to or cannot access standard treatments. Participants will receive JSKN021 intravenously at various dose levels across multiple sequential cohorts, including dose escalation and dose optimization groups. The study will monitor for adverse events, determine the optimal biological dose, and evaluate preliminary tumor responses over a period that may extend up to 24 months. During the trial, participants will have regular visits for treatment administration and safety assessments, including laboratory tests and imaging to measure tumor response. Researchers will track treatment-emergent side effects, dose-limiting toxicities, pharmacokinetic parameters, and survival outcomes. Participants are expected to comply with all study procedures and follow-up visits throughout the study duration.

CONDITIONS

Brief Title

A Phase I Study of JSKN021 in Advanced Solid Tumors

Research Team

J

Jian Zhang, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here